Yes I know all that. And I'll say again that most broker and analyst reports, recommendations including valuations are more akin to kindergarten fingerprinting than a masterpiece. Most aren't worth the paper they are written on. Best bet is for people to do their own research.
Ann: AstraZeneca presents 1st DEP candidate as Bcl2/xL inhibitor, page-78
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.7¢ |
Change
-0.001(1.02%) |
Mkt cap ! $40.48M | |||
| Open | High | Low | Value | Volume |
| 9.6¢ | 10.0¢ | 9.6¢ | $5.703K | 58.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.8¢ | 20000 | 1 |
View Market Depth
| Last trade - 15.41pm 11/10/2024 (20 minute delay) ? |
| SPL (ASX) Chart |